PCSK9: From discovery to therapeutic applications.

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol metabolism by promoting low-density lipoprotein receptor (LDLR) degradation.
• Gain-of-function mutations in PCSK9 cause autosomal dominant hypercholesterolemia, while loss-of-function mutations are linked to lower LDL cholesterol and reduced coronary heart disease risk.

Purpose of the Study:

• To evaluate PCSK9 inhibition as a therapeutic strategy for lowering LDL cholesterol.
• To assess the efficacy and tolerability of monoclonal antibodies targeting PCSK9.

Main Methods:

• Review of human data from phase II studies involving monoclonal antibodies (alirocumab and evolocumab) that inhibit PCSK9 binding to LDLR.
• Evaluation of efficacy in hypercholesterolemic patients, including those with familial hypercholesterolemia, statin intolerance, and in monotherapy.

Main Results:

• Monoclonal antibodies targeting PCSK9 demonstrated effective reduction of atherogenic lipoproteins.
• LDL cholesterol reduction of up to 70% was observed with high-dose treatments.
• These agents were generally well tolerated in phase II studies.

Conclusions:

• PCSK9 inhibition represents a promising therapeutic strategy for lowering LDL cholesterol.
• Monoclonal antibodies targeting PCSK9 are effective and well-tolerated, offering a new option for managing hypercholesterolemia.
• Ongoing phase III trials will further elucidate the long-term efficacy and safety of these agents.